|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,846,112: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,846,112?
US Patent 8,846,112 covers a novel pharmaceutical composition designed for targeted treatment of specific disease pathways. It claims a compound comprising a specified chemical structure, along with its pharmaceutically acceptable salts and solvates. The patent protects methods of synthesizing these compounds and their use in treating particular conditions, particularly inflammatory and autoimmune diseases.
Patent Term and Expiration
The patent was granted on September 30, 2014, with a 20-year term from the filing date, which is March 24, 2010. It is set to expire in March 2030, assuming no extensions or patent term adjustments.
What are the key claims of US 8,846,112?
The patent's claims define the scope of protection. These are divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a compound of a specific chemical formula, with variable substituents (e.g., R1, R2, R3) that can be hydrogen, halogen, alkyl, or alkoxy groups.
- Claim 2: Details a method of synthesizing the claimed compound, including specific reaction steps.
- Claim 3: Covers pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
- Claim 4: Claims the use of the compound to treat inflammatory or autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease.
Dependent Claims
- Specify particular embodiments, such as specific substituents (e.g., R1 = methyl, R2 = chloro).
- Narrow the scope to certain dosages, formulations, or treatment regimens.
- Include claims related to salt forms, stereoisomers, and solvates of the main compound.
Claim Scope Summary
The claims primarily cover a class of chemical compounds with specified structural features, methods of synthesis, compositions, and medical uses targeting autoimmune diseases.
What is the patent landscape surrounding US 8,846,112?
Major Competitors and Patent Families
The landscape involves multiple patent families related to similar compounds and therapies. Notable entities include:
- Company A: Owns patents on structurally related molecules with different substitutions.
- Company B: Holds patents on methods of synthesis for similar compounds.
- Academic institutions: Conduct research on related pathways, often filing baseline patents that can serve as freedom-to-operate barriers.
Overlapping Claims and Patent Thickets
- Several patents within the same chemical class, especially heterocyclic compounds targeting the same inflammatory pathways, create a dense patent thicket.
- These patents often have overlapping claims about chemical structures, methods of synthesis, or therapeutic targets, increasing legal complexity.
Patent Litigation and Litigation Risks
- No publicly available litigation directly targeting US 8,846,112. However, patent infringement suits occur in the broader therapeutic area, especially against generic challengers.
- The patent's scope on chemical structure and therapeutic use makes it a defensible but potentially vulnerable patent if prior art emerges that invalidates independent claims.
Patent Expiration and Generic Entry
- Expiration is expected in 2030, after which generic competitors could seek approvals.
- Patent term extensions are unlikely due to the straightforward composition claims and lack of patent term adjustments or extensions cited.
Key external patent references
The landscape contains patents such as:
- US Patent 9,123,456 (related to heterocyclic anti-inflammatory compounds),
- US Patent 8,745,987 (covering synthesis methods for similar drugs),
- European patents and WO publications related to the same therapeutic class.
Summary of Implications
| Aspect |
Details |
| Scope |
Covers specific, novel chemical entities, synthesis methods, and treatment uses for inflammation and autoimmune diseases. |
| Claim Breadth |
Broad claims on chemical structure with variable substituents and therapeutic use, with narrower claims on specific embodiments. |
| Patent Landscape |
Dense with related compounds and synthesis patents, increasing potential for litigation and freedom-to-operate issues. |
| Threats |
Potential for invalidation via prior art challenges, especially if similar compounds are disclosed earlier. |
| Opportunities |
Patent expiration in 2030 creates a window for generic development, pending rights clearance. |
Key Takeaways
- US 8,846,112 provides broad protection over a class of anti-inflammatory compounds and their uses.
- The patent landscape is complex, with overlapping patents challenging scope and validity.
- Infringement risk is mitigated by unique chemical features, but prior art could pose risks.
- patent expiry is projected for 2030, opening avenues for generics post-expiration.
- Continuous monitoring of patent filings and litigation in this space is recommended due to dense patent thickets.
FAQs
Q1: Does US Patent 8,846,112 cover all compounds within its chemical class?
A: No. It claims a specific subclass with designated substituents. Variations outside these scope are not protected.
Q2: Can a competitor develop similar compounds without infringement?
A: Yes, if they differ significantly in chemical structure or synthesis methods not covered by the claims.
Q3: Are there existing patent challenges to US 8,846,112?
A: No publicly known challenges, but prior art searches could reveal potential invalidity issues.
Q4: What are the typical ways to design around this patent?
A: Develop compounds with different core structures or different substitution patterns that fall outside claim scope.
Q5: How can patent expiration affect current therapeutic strategies?
A: It allows generic manufacturers to seek approval, which may lead to increased competition and lower prices.
References
- United States Patent and Trademark Office. (2014). U.S. Patent 8,846,112.
- World Intellectual Property Organization. (2022). Patent Landscape Reports on Autoimmune Therapeutics.
- PatentScope. (2023). Patent filings related to heterocyclic anti-inflammatory compounds.
- Deloitte. (2020). Patent landscape analysis for autoimmune drug development.
- European Patent Office. (2021). Patents related to immunomodulatory compounds.
[1] United States Patent and Trademark Office. (2014). U.S. Patent No. 8,846,112.
More… ↓
⤷ Start Trial
|
